China’s April 2026 supply chain regulations eliminate transition periods and empower Beijing to restrict exports from U.S. pharma firms conducting routine compliance — including forced labor due diligence. U.S. reliance on Chinese API ranges from 8% to 47%, while generics constitute 90% of prescriptions but only 13.1% of drug spending. A 2025 CSIS analysis identifies regulatory complexity, permitting delays, and workforce gaps as key barriers to reshoring. Gerren McHam of the API Innovation Center stresses that audit protocols now carry geopolitical risk, requiring integrated investment, procurement reform, and demand signaling to build resilient domestic capacity.
According to www.pharmaceuticalcommerce.com, China’s April 2026 Regulations on Industrial and Supply Chain Security — enacted immediately with no transition period — now allow Beijing to impose export restrictions on U.S. pharmaceutical companies for routine compliance with U.S. law, including forced labor due diligence under the Uyghur Forced Labor Prevention Act.
Direct Compliance Conflict Emerges
The regulations, paired with companion rules countering foreign extraterritorial jurisdiction, grant Chinese regulators broad authority to investigate and designate companies as “malicious entities” — triggering import and export restrictions. As Mayer Brown noted in its May 5, 2026 analysis, actions standard under U.S. regulatory practice — such as auditing a Chinese supplier or pausing shipments — now carry tangible retaliation risk.
According to the report, these measures transform what had been a chronic vulnerability into an acute compliance crisis. For U.S. generic drug manufacturers — which rely heavily on Chinese-sourced active pharmaceutical ingredients (API) — the operational stakes are immediate and high. The Brookings Institution cites estimates of U.S. dependence on Chinese-made API ranging from 8% to 47%; other analyses suggest China controls 80–90% of global API supply.
Structural Barriers to Reshoring
A September 29, 2025 Center for Strategic and International Studies (CSIS) analysis underscores why domestic API production remains elusive: generic medicines account for approximately 90% of U.S. prescriptions but only 13.1% of total drug spending — a cost dynamic that severely constrains margins available for reshoring investment.
The same CSIS report found that tariffs and executive orders alone cannot overcome three persistent constraints: regulatory complexity, permitting delays, and workforce gaps in U.S. pharmaceutical manufacturing. These structural barriers persist despite federal initiatives like the Department of Health and Human Services’ partnership with the API Innovation Center.
Operational Implications for Supply Chain Teams
To clarify implementation risks and mitigation pathways, Pharmaceutical Commerce interviewed Gerren McHam, vice president of government and external affairs at the API Innovation Center. McHam emphasized that supply chain teams must now treat U.S. compliance activities — previously viewed as low-risk governance functions — as potential triggers for Chinese countermeasures.
He stressed that building a viable domestic API base requires more than capital alone: it demands coordinated action across three levers — targeted public and private investment, consistent demand signaling from payers and federal procurement programs, and reform of sourcing practices that currently prioritize lowest-cost bids over resilience metrics. “Routine audits are no longer just about due diligence — they’re geopolitical exposure points,” McHam said.
“Actions that are routine under US law, such as auditing a Chinese supplier, pausing shipments, and conducting forced labor due diligence… can now trigger Chinese investigations and placement on a ‘malicious entity’ list.” — Mayer Brown, “China Expands Its Playbook,” May 5, 2026
Pathways to Resilience
McHam outlined three non-negotiable conditions for successful API reshoring: first, sustained multi-year funding aligned with FDA’s Manufacturing Readiness Framework; second, binding federal procurement commitments — such as requiring 25% of all federally purchased generics to contain domestically sourced API by 2028; and third, harmonized data standards enabling real-time traceability across API batches, starting with pilot programs launched in Q3 2026.
The CSIS analysis further notes that current U.S. domestic API capacity meets less than 5% of total demand — a gap widening amid tightening Chinese export controls. Without integrated policy intervention, McHam warned, supply chain teams face escalating trade-off decisions between legal compliance and commercial continuity.
Source: pharmaceuticalcommerce.com
Compiled from international media by the SCI.AI editorial team.
